-
Views
-
Cite
Cite
M. V. Zunzunegui-Pastor, F. M. Gómez-Trujillo, J. S. Luque-Martin, J. J. Sánchez-Luque, C. Ortiz-Garcıéa, M. J. Ferreras-Duarte, I. García-Caravaca, P-94: Should the routinary determination of plasmatic fibrinogen as vascular risk indicative parameter be included in the metabolic syndrome patient?, American Journal of Hypertension, Volume 14, Issue S1, April 2001, Pages 60A–61A, https://doi.org/10.1016/S0895-7061(01)01633-8
Close - Share Icon Share
Abstract
47 patients meeting all the criteria for the metabolic syndrome were randomly selected by systematic sampling from their primary care area, filling in a multiparametric data collection record-card, measuring the fibrinogenemia levels and using the program JMP from the SAS Institute to carry out the statistical procedure. Considerig the presence or not of the macro or micro vascular events as the qualitative variable and the fibrinogenemia levels as the quantitative variable. The results were: age 65,4 +/- 8,13 years; sex: 34,04 % males and 65,95 females; median age at the onset of hypertension 54,29 +/- 11,92 years; median age at the onset of diabetes 56,61 +/- 10,57 years, median age at the onset of dyslipemia 59,36 +/- 8,50 years; hip-waist index was 0,97 +/- 0,04 for males and 0,89 +/- 0,03 for females.
Hyperfibrinogenemia was found in the metabolic syndrome analyzed population (425,80+/-121,88 mg/dl), with a statistically significant association (p < 0,026391) between high levels of plasma fibrinogen and the vascular events risk in the metabollic syndrome patients. A mathematical model was created in order to predict the cardiovascular risk of each patient depending on the plasmatic fibrinogen levels.
Regresion Analysis: P= e-2.3396549+(0.00607972xb1) / 1+e-2.3396549+(0.00607972xb1); were b1 = plasmatic fibrinogen. If p< 0,25 the patient have low cardiovascular risk; If p between 0,25-0,50 intermediate cardiovascular risk; if p between 0,50-0,75, high cardiovascular risk and when p >0,75 very high cardiovascular risk.
